Genetic Investigation of Solid Tumors Cohort
|ClinicalTrials.gov Identifier: NCT01005225|
Recruitment Status : Completed
First Posted : October 30, 2009
Last Update Posted : June 12, 2014
|Condition or disease|
|Prostate Cancer Colon Cancer|
Recent studies in human genetics have discovered several intervals in the human genome containing inherited variants that are statistically associated with the propensity to develop solid tumors. Even though it has been firmly established that if an individual carries these DNA variants they have an increased chance of developing a solid tumor the underlying biological mechanisms for most of these associations are largely unknown.
In addition to inherited DNA variants that are associated with the development of solid tumors it is well established that during the development and growth of solid tumors the DNA in these cancer cells undergo somatic changes (mutations). These somatic DNA changes have been studied over the past decade and frequently are specific chromosomal translocations and amplifications associated with the development of particular solid tumors. In some instances, examining the chromosomal translocation and amplification has lead to the discovery of proteins contributing to solid tumor pathology.
the human 8q24 interval that has strong genetic associations with solid tumor development has also been noted as frequently amplified in solid tumors and serves as a predictor of poor survival in prostate cancers.
|Study Type :||Observational|
|Actual Enrollment :||25 participants|
|Official Title:||Genetic Investigation of Solid Tumors Cohort|
|Study Start Date :||February 2008|
|Primary Completion Date :||May 2014|
|Study Completion Date :||May 2014|
Participants 18 years of age or older who have been diagnosed with a solid tumor or benign hyperplasia that needs surgical removal will be included in this study.
- Solid tumor biological insights [ Time Frame: Study completion ]Obtain blood samples, solid tumor and/or benign hyperplasia samples, and in some instances normal tissue in order to gain biological insights into cancer (solid tumors) through population genetics and genomics.
Biospecimen Retention: Samples With DNA
Approximately 19.5 milliliters (mls) of blood will be collected in (2 x 8.5 ml) PAXgene DNA tubes and (1 x 2.5 ml) PAXgene RNA tube.
Solid tumor and/or benign hyperplasia samples will be collected from the participants during surgery scheduled for standard medical care.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01005225
|United States, California|
|San Diego, California, United States, 92037|
|Principal Investigator:||James Mason, MD||Scripps Health|